Business
Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program (CTEP). The CRADA will focus on advancing XPOVIO (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, which blocks the cellular protein XPO1. XPO1 plays a key role in regulating the activity of tumor suppressor proteins and other oncoproteins relevant in cancer cell biology and cancer cell survival. XPO1 may be an important, novel target in the treatment of numerous cancer types. XPO1 is frequently overexpressed in both hematologic and solid tumors, and the degree of XPO1 over-expression correlates with higher tumor grade and poor overall patient survival.\n “We are looking forward to combining our expertise with those at the NCI to explore XPOVIO’s potential benefit in a wider range of cancer indications,” said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. “The studies conducted under this partnership will be designed with the goal of identifying and optimizing combinations and indications that hold the greatest chance of clinical success. This CRADA is an important collaboration for Karyopharm as we work to realize the full potential of XPOVIO and bring this novel medicine to as many patients as possible.” Under the terms of the CRADA, the NCI will collaborate with Karyopharm on studies to investigate the safety and efficacy of XPOVIO in various oncology indications, based on encouraging anti-tumor activity observed in earlier studies. As data from the NCI-sponsored studies and other Karyopharm-sponsored studies emerge, the NCI and Karyopharm plan to collaborate on trials to complement and support the further development of XPOVIO that could address important patient unmet medical need. The NCI may also support non-clinical studies to explore important future combinations of XPOVIO with other targeted or standard of care cancer agents. “We are excited to work with the NCI on this new initiative which may lead to important research that could address important unmet needs for cancer patients,” stated Jatin Shah, MD, Executive Vic...